Show simple item record

dc.contributor.authorBarge-Caballero, Gonzalo
dc.contributor.authorBarge-Caballero, Eduardo
dc.contributor.authorMarzoa Rivas, Raquel
dc.contributor.authorPaniagua-Martín, María J.
dc.contributor.authorBarrio-Rodríguez, Alfredo
dc.contributor.authorNaya, Carmen
dc.contributor.authorBlanco-Canosa, Paula
dc.contributor.authorGrille Cancela, Zulaika
dc.contributor.authorVázquez Rodríguez, José Manuel
dc.contributor.authorCrespo-Leiro, María Generosa
dc.date.accessioned2017-06-15T07:39:21Z
dc.date.available2017-06-15T07:39:21Z
dc.date.issued2015-04-23
dc.identifier.citationBarge-Caballero G, Barge-Caballero E, Marzoa-Rivas R, et al. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results. Transpl Int. 2015;28(9):1034-1041es_ES
dc.identifier.issn1432-2277
dc.identifier.urihttp://hdl.handle.net/2183/19174
dc.description.abstract[Abstract] We conducted an observational study of 30 heart transplant recipients with serum low-density lipoprotein cholesterol (LDL-c) >100 mg/dl despite previous statin therapy, who were treated with rosuvastatin 10 mg daily (5 mg in case of renal dysfunction). Serum lipids, creatine phosphokinase (CPK), bilirubin, and hepatic enzymes were prospectively measured 2, 4, and 12 weeks after the initiation of the drug. Clinical outcomes of patients who continued on long-term rosuvastatin therapy beyond this 12-week period were reviewed in February 2015. Over the 12-week period following rosuvastatin initiation, serum levels of total cholesterol (TC) and LDL-c and the ratio TC/high-density lipoprotein cholesterol (HDL-c) decreased steadily (P < 0.001). Average absolute reductions of these three parameters were –48.7 mg/dl, –46.6 mg/dl, and –0.9, respectively. Seventeen (57%) achieved a serum LDL-c < 100 mg/dl. No significant changes from baseline were observed in serum levels of triglycerides, HDL-c, hepatic enzymes, bilirubin, or CPK. Twenty-seven (90%) patients continued on long-term therapy with rosuvastatin over a median period of 3.6 years, with no further significant variation in lipid profile. The drug was suspended due to liver toxicity in 1 (3.3%) patient and due to muscle toxicity in 2 (6.7%) patients. All adverse reactions resolved rapidly after rosuvastatin withdrawal. Our study supports rosuvastatin as a reasonable alternative for heart transplant recipients with hypercholesterolemia and therapeutic failure of other statin regimens.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.urihttp://dx.doi.org/10.1111/tri.12585es_ES
dc.rightsThis is the peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.es_ES
dc.subjectHeart transplantationes_ES
dc.subjectHypercholesterolemiaes_ES
dc.subjectRosuvastatines_ES
dc.titleClinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety resultses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleTransplant Internationales_ES
UDC.volume28es_ES
UDC.issue9es_ES
UDC.startPage1034es_ES
UDC.endPage1041es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record